Prostate cancer is the second most common cause of cancer death in men in the United States. The most common sites of metastasis include the bone, lymph nodes, lung, liver, pleura, and adrenal glands, whereas metastatic prostate cancer involving the gastrointestinal tract has been rarely reported. A 64-year-old African-American man with a history of prostate cancer presented with anemia. He reported the passing of dark colored stools but denied hematemesis or hematochezia. Colonoscopy revealed circumferential nodularity, and histology demonstrated metastatic carcinoma of the prostate. Esophagogastroduodenoscopy showed hypertrophic folds in the gastric fundus, and microscopic examination revealed tumor cells positive for prostate-specific antigen. Bone scanning and computed tomography of the abdomen and pelvis did not show metastasis. It is crucial to distinguish primary gastrointestinal cancer from metastatic lesions, especially in patients with a history of cancer at another site, for appropriate management.
Introduction
Prostate cancer is the second most common cause of cancer death in men in the United States. In the United States, the ageadjusted number of new cases of prostate cancer was 147.8 per 100,000 men per year based on 2007~2011 data and the age-adjusted number of deaths was 23.0 per 100,000 men per year based on 2006~2010 data. According to 2008~2010 data, approximately 15 .3% of men will be diagnosed with prostate cancer at some point during their lifetime, and in 2011, an estimated 2,707,821 men were living with prostate cancer in the United States. 1 The most common sites of prostate cancer metastasis include the bone, lymph nodes, lungs, liver, pleura, and adrenal glands. 2 Rarely has metastatic prostate cancer been reported to involve the gastrointestinal tract.
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Here, we report the case of a 64-year-old man with prostate cancer that had metastasized to the rectum and stomach.
Case Report antigen. These findings were consistent with a diagnosis of metastatic, poorly differentiated carcinoma of the prostate.
Since it was known that the patient had hormone-refractory prostate cancer, he was started on docetaxel and received 3 cycles until February 2013, at which point he was lost to follow-up. In
May 2013, he was admitted because of worsening of his anemia, and esophagogastroduodenoscopy was performed. This revealed hypertrophic folds in the gastric fundus (Fig. 3) . Microscopic examination revealed sheets of atypical cells with prominent nucleoli and no glandular pattern within the gastric lamina propria (Fig.   4 ). Immunohistochemical studies demonstrated that the tumor cells were positive for prostate specific antigen (PSA) and alphamethylacyl-coenzyme A racemase (AMACR, P504S) (Fig. 5) . The patient's serum PSA level was more than 1,000 mg/dl at that time.
A bone marrow biopsy did not reveal any malignant infiltration.
The bone scan, as well as the CT scan of the abdomen and pelvis, showed no metastases but showed retroperitoneal lymphadenopathy. At that time, the patient had an Eastern Cooperative Oncology
Group performance status of 3. The patient and family refused further chemotherapy for metastatic prostate cancer and opted for palliative care instead. The patient was admitted multiple times for Metastatic prostate cancer has a poor prognosis and median survival time ranges from 1 to 3 years. 3 Prostate cancer preferentially spreads to the skeleton. More than 80% of men who die from prostate cancer are identified with bone metastases at autopsy. histochemical marker that has been found to be consistently upregulated in prostate carcinoma. 17, 18 Treatment for metastatic prostate cancer is palliative. Androgen 
